← 返回前沿论文

利用可调控膜结合 IL15 从免疫排斥型软骨肉瘤中生成强效细胞毒性 TIL(肿瘤浸润淋巴细胞)

英文原题:Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated from Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15.

PubMed 2026/06/02(内容时间) Cancer Immunol Res Q1 · IF 7.9(JCR 2025)

研究概要

这些结果提示,有可能为免疫排斥型肿瘤患者开发出有效的无 IL2 的 TIL 疗法。

中文摘要

自体TIL(肿瘤浸润淋巴细胞)疗法在黑色素瘤、宫颈癌和肾癌等免疫“热”肿瘤中显示出良好疗效。然而,对于肿瘤突变负荷较低的“冷”肿瘤(如许多肉瘤),生成具有肿瘤杀伤能力的TIL仍具挑战,原因包括淋巴细胞向肿瘤微环境(TME)浸润有限、肿瘤抗原特异性高亲和力T细胞频率低,以及TME中免疫耐受机制尚未完全阐明。本研究报告了从免疫排斥、细胞稀少的软骨肉瘤活检样本中成功生成并扩增经可调控膜结合型IL-15工程化的TIL(cytoTIL15细胞)。在无需外源性IL-2的情况下,这些细胞在培养和肿瘤球模型中均具有强效肿瘤杀伤能力。TME的全面空间分析显示,广泛存在的胶原和髓系细胞浸润是主要耐受机制;淋巴细胞浸润则主要局限于肿瘤周边区域,这一点对采集肿瘤组织制备TIL具有参考意义。此外,我们证明IL-15降低了从TIL克隆型分离出的T细胞受体信号阈值,并增强其在自体三维肿瘤模型中的浸润和细胞毒性。这些结果提示,有可能为免疫排斥型肿瘤患者开发有效的无IL-2 TIL疗法。

展开英文摘要原文

Autologous tumor-infiltrating lymphocyte (TIL) cell therapy is showing promising efficacy against immunologically "hot" tumors such as melanoma, cervical cancer, and renal cancer. However, generation of tumoricidal TILs from "cold" tumors with a low tumor mutational burden, such as many sarcoma types, poses a challenge due to limited infiltration of the tumor microenvironment (TME) with lymphocytes, low frequencies of tumor antigen-specific, high-affinity T cells, and incompletely understood mechanisms of immune-resistance prevailing in the TME. Here, we report the successful generation and expansion of TILs engineered with regulatable, membrane-bound IL15 (cytoTIL15 cells) from immune-excluded, paucicellular chondrosarcoma biopsies largely consisting of collagenous matrix and demonstrate that these cells have potent tumor-killing capacity in cell culture and in tumor spheroid models in the absence of exogenous IL2. Comprehensive spatial profiling of the TME revealed ubiquitous collagen and myeloid infiltration as major resistance mechanisms, whereas lymphocytic infiltration was largely restricted to peripheral regions of the tumors, a relevant consideration when sampling these tumors for TIL harvest. Moreover, we demonstrate that IL15 reduced the signaling threshold of T-cell receptors isolated from TIL clonotypes, increasing their infiltration and cytotoxicity in autologous 3D tumor models. These results suggest the possibility of developing an effective IL2-free TIL therapy for patients with immune-excluded tumors.

论文信息

作者
Ao Z、Al-Marayaty R、Aksoy BA、Obeidin F、Burga R、Attar S、Peabody T、Hermida de Viveiros P
第一作者单位
Obsidian Therapeutics, Cambridge, Massachusetts.United Kingdom
通讯作者单位
Northwestern University , Feinberg School of Medicine, Chicago, Illinois.United States
期刊
Cancer immunology research2026 Jun 2
原文标识
PubMed 41719158 · DOI 10.1158/2326-6066.CIR-25-1016